Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
HIMS · NYSE · United States · Services-Offices & Clinics Of Doctors Of Medicine
In shortHims & Hers Health, Inc. is profitable, generates cash and carries moderate debt, with revenue growing (+59.0% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 4.5% | 32/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 5.5% | 42/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 25.2% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 5.5% | 37/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.90× | 92/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.80× | 11/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 2.47× | 44/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 1.61 | 13/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 2.4% | 30/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.45× | 18/100 |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 14.0% | 59/100 |
| Operating margin volatility | 19.4% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 64.5% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
2 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 272 | 527 | 872 | 1,477 | 2,348 |
| Cost of revenue | 67 | 118 | 157 | 303 | 614 |
| Gross profit | 204 | 409 | 715 | 1,173 | 1,733 |
| Selling, general & admin | 184 | – | – | – | – |
| Operating income | (115) | (69) | (29) | 62 | 106 |
| Interest expense | 0 | – | – | – | – |
| Pre-tax income | (111) | (66) | (22) | 72 | 124 |
| Income tax | (3.1) | (0) | 2 | (54) | (4.4) |
| Net income | (108) | (66) | (24) | 126 | 128 |
| Diluted EPS | −$0.58 | −$0.32 | −$0.11 | $0.53 | $0.51 |
| Diluted shares (millions) | 187 | 205 | 209 | 237 | 258 |
2 older years available with the 10-year history. Essential plan, from €8.25/month →
1.61 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 10, 2026